We used an SGLT2 inhibitor, ERTU, to counteract metabolic aberrations associated with heart failure and to elucidate the role of mitochondrial dysfunction in the progression of dilated cardiomyopathy in a mouse model with cardiac myocyte-specific overexpression of Gαq. The gene discussed is GNAQ; the disease is dilated cardiomyopathy.